The Food and Drug Administration (FDA) has approved Rybrevant Faspro™, a subcutaneous (SC) formulation of amivantamab for all indications approved for the ...
TRITON3 trial data support FDA traditional approval of rucaparib for treating adults with BRCA-mutated metastatic castration-resistant prostate cancer.
HealthDay News — Flu season is getting an early start in New York City, with doctors reporting a sharp jump in cases weeks sooner than normal.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback